ThromboGenics NV Aktie

Kaufen

Verkaufen

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Bei einem anderen Broker handeln

WKNA0J30B

ISINBE0003846632

SymbolTBGNF

ThromboGenics NV Aktien News

Sortieren:Datum Meistgelesen

25.07.24GlobeNewswireOxurion Share Consolidation

24.07.24GlobeNewswireOxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024

19.07.24GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

18.07.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

11.07.24GlobeNewswireOxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024

08.07.24GlobeNewswireOxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production

04.07.24GlobeNewswireOxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024

07.06.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

04.06.24GlobeNewswireOxurion Announces Extraordinary General Shareholders’ Meeting

27.05.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

23.05.24GlobeNewswireOxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024

23.05.24GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

16.05.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

14.05.24GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

13.05.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

06.05.24GlobeNewswireImportant Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD

25.04.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

15.04.24GlobeNewswirePublication Annual Report – Annual Shareholders' Meeting

11.04.24GlobeNewswireOxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

10.04.24GlobeNewswireOxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up

05.04.24GlobeNewswirePostponement Annual Shareholders Meeting - Amendment financial calendar

28.03.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

27.03.24GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version

26.03.24GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

25.03.24GlobeNewswireOXURION announces its presence at the Paris SmallCap event on March 28, 2024.

22.03.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

21.03.24GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

13.03.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

07.03.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

05.03.24GlobeNewswireOxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up

04.03.24GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

22.01.24GlobeNewswireOxurion Announces New Strategic Orientation to De-risk and Diversify

19.01.24GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

17.01.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

12.01.24GlobeNewswireOxurion Receives Transparency Notification from Atlas Special Opportunities LLC

28.12.23GlobeNewswireOxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas

01.12.23GlobeNewswireOxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

20.11.23GlobeNewswireOxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

19.11.23GlobeNewswireInformation on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

16.11.23GlobeNewswireOxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year

ThromboGenics NV News

ThromboGenics NV News: auf dieser Seite finden Sie alle ThromboGenics NV News und Nachrichten zur ThromboGenics NV Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch ThromboGenics NV News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um ThromboGenics NV News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.